Last checked at 13 May 2008 06:00
| For Immediate Release | 13 May 2008 |
ImmuPharma PLC
Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM
Immupharma has selected the trademark LUPUZOR TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130).
Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.”
For further information please contact:
| ImmuPharma PLC: |
|
| Dimitri Dimitriou, Chief Executive Officer | +44 20 7152 4080 |
| Dr Robert Zimmer, President & Chief Scientific Officer | + 33 389 32 76 50 |
| Richard Warr, Chairman | +44 20 7152 4080 |
|
|
|
| Buchanan Communications | + 44 20 7466 5000 |
| Lisa Baderoon |
|
| Rebecca Skye Dietrich |
|
|
|
|
| Panmure Gordon & Co |
|
| Andrew Burnett | +44 151 243 0963 |
For company information, visit www.immupharma.com